Early prediction of pathologic response to neoadjuvant therapy in breast cancer: systematic review of the accuracy of MRI.
暂无分享,去创建一个
N Houssami | S Ciatto | L Irwig | P Macaskill | S. Ciatto | L. Irwig | M. Brennan | P. Macaskill | N. Houssami | E. Mamounas | G. von Minckwitz | F. Sardanelli | G. Minckwitz | G von Minckwitz | F Sardanelli | M L Marinovich | E Mamounas | M Brennan | E. Mamounas | M. Marinovich | Meagan E Brennan | M. Brennan
[1] A. Miller,et al. Reporting results of cancer treatment , 1981, Cancer.
[2] Sarah Lord,et al. When Is Measuring Sensitivity and Specificity Sufficient To Evaluate a Diagnostic Test, and When Do We Need Randomized Trials? , 2006, Annals of Internal Medicine.
[3] G. Hortobagyi,et al. Can early response assessment guide neoadjuvant chemotherapy in early-stage breast cancer? , 2008, Journal of the National Cancer Institute.
[4] S. Rodenhuis,et al. Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] A. Schneeweiss,et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] Andreas Makris,et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] Kenneth G A Gilhuijs,et al. Dynamic contrast-enhanced MRI for prediction of breast cancer response to neoadjuvant chemotherapy: initial results. , 2008, AJR. American journal of roentgenology.
[8] M. Tozaki,et al. Predicting pathological response to neoadjuvant chemotherapy in breast cancer with quantitative 1H MR spectroscopy using the external standard method , 2010, Journal of magnetic resonance imaging : JMRI.
[9] Thomas E. Yankeelov,et al. Current and Future Trends in Magnetic Resonance Imaging Assessments of the Response of Breast Tumors to Neoadjuvant Chemotherapy , 2010, Journal of oncology.
[10] A. Luini,et al. Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features , 2010, Breast Cancer Research and Treatment.
[11] P. Bossuyt,et al. BMC Medical Research Methodology , 2002 .
[12] Roberto Orecchia,et al. Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group. , 2010, European journal of cancer.
[13] Hon J. Yu,et al. Predicting pathologic response to neoadjuvant chemotherapy in breast cancer by using MR imaging and quantitative 1H MR spectroscopy. , 2009, Radiology.
[14] S. Loibl,et al. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. , 2008, Journal of the National Cancer Institute.
[15] Carmel Hayes,et al. Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging: initial clinical results. , 2006, Radiology.
[16] D. Bluemke,et al. Multiparametric magnetic resonance imaging, spectroscopy and multinuclear (²³Na) imaging monitoring of preoperative chemotherapy for locally advanced breast cancer. , 2010, Academic radiology.
[17] Peter Gibbs,et al. Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer. , 2006, Magnetic resonance imaging.
[18] Jun Li,et al. Quantitative analysis of clinical dynamic contrast-enhanced MR imaging for evaluating treatment response in human breast cancer. , 2010, Radiology.
[19] Daniele Regge,et al. Monitoring Response to Primary Chemotherapy in Breast Cancer using Dynamic Contrast-enhanced Magnetic Resonance Imaging , 2004, Breast Cancer Research and Treatment.
[20] B. Naume,et al. Neoadjuvant chemotherapy in breast cancer-response evaluation and prediction of response to treatment using dynamic contrast-enhanced and diffusion-weighted MR imaging , 2010, European Radiology.
[21] P. Fasching,et al. Correlation of various pathologic complete response (pCR) definitions with long-term outcome and the prognostic value of pCR in various breast cancer subtypes: Results from the German neoadjuvant meta-analysis. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] I. Makhoul,et al. Neoadjuvant systemic treatment of breast cancer , 2011, Journal of surgical oncology.
[23] C Gatsonis,et al. Validation of novel imaging methodologies for use as cancer clinical trial end-points. , 2009, European journal of cancer.
[24] Johannes B Reitsma,et al. Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies , 2006, BMC medical research methodology.
[25] Andreas Makris,et al. Early Changes in Functional Dynamic Magnetic Resonance Imaging Predict for Pathologic Response to Neoadjuvant Chemotherapy in Primary Breast Cancer , 2008, Clinical Cancer Research.
[26] A. Schneeweiss,et al. S3-2: Neoadjuvant Chemotherapy Adapted by Interim Response Improves Overall Survival of Primary Breast Cancer Patients - Results of the GeparTrio Trial. , 2011 .
[27] S. Sener,et al. Neoadjuvant therapy for breast cancer , 2010, Journal of surgical oncology.
[28] F. Sardanelli,et al. Breast MRI using a high-relaxivity contrast agent: an overview. , 2011, AJR. American journal of roentgenology.
[29] T. Taguchi,et al. Good Response to Paclitaxel Predicts High Rates of Pathologic Complete Response for Breast Cancer Patients Treated Preoperatively with Paclitaxel Followed by 5-Fluorouracil, Epirubicin and Cyclophosphamide , 2008, Oncology.
[30] T. Churches. A proposed architecture and method of operation for improving the protection of privacy and confidentiality in disease registers , 2003, BMC medical research methodology.
[31] J. Bryant,et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. , 2001, Journal of the National Cancer Institute. Monographs.
[32] D. Narayanan,et al. Breast cancer: comparative effectiveness of positron emission mammography and MR imaging in presurgical planning for the ipsilateral breast. , 2011, Radiology.
[33] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[34] L. Walker,et al. Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. , 2002, Clinical breast cancer.
[35] D. Collins,et al. Primary human breast adenocarcinoma: imaging and histologic correlates of intrinsic susceptibility-weighted MR imaging before and during chemotherapy. , 2010, Radiology.
[36] N. deSouza,et al. Functional magnetic resonance: biomarkers of response in breast cancer , 2011, Breast Cancer Research.
[37] F. Penault-Llorca,et al. Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer , 2002, British Journal of Cancer.
[38] B. Corcioni,et al. Contrast-enhanced US and MRI for assessing the response of breast cancer to neoadjuvant chemotherapy(). , 2008, Journal of ultrasound.
[39] M. Meunier,et al. MRI for surgical planning in patients with breast cancer who undergo preoperative chemotherapy. , 2004, AJR. American journal of roentgenology.
[40] J E Husband,et al. Evaluation of the response to treatment of solid tumours – a consensus statement of the International Cancer Imaging Society , 2004, British Journal of Cancer.
[41] Sibel Kul,et al. Contrast-enhanced MR angiography of the breast: Evaluation of ipsilateral increased vascularity and adjacent vessel sign in the characterization of breast lesions. , 2010, AJR. American journal of roentgenology.
[42] Fiona J Gilbert,et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.